259 related articles for article (PubMed ID: 31568682)
21. Lineage-Restricted OLIG2-RTK Signaling Governs the Molecular Subtype of Glioma Stem-like Cells.
Kupp R; Shtayer L; Tien AC; Szeto E; Sanai N; Rowitch DH; Mehta S
Cell Rep; 2016 Sep; 16(11):2838-2845. PubMed ID: 27626655
[TBL] [Abstract][Full Text] [Related]
22. ING5 activity in self-renewal of glioblastoma stem cells via calcium and follicle stimulating hormone pathways.
Wang F; Wang AY; Chesnelong C; Yang Y; Nabbi A; Thalappilly S; Alekseev V; Riabowol K
Oncogene; 2018 Jan; 37(3):286-301. PubMed ID: 28925404
[TBL] [Abstract][Full Text] [Related]
23. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
24. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.
Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Ciner F; Mertsoylu H; Tufan K
J Neurooncol; 2018 Sep; 139(2):411-419. PubMed ID: 29696530
[TBL] [Abstract][Full Text] [Related]
26. Survival improvements with adjuvant therapy in patients with glioblastoma.
Jayamanne D; Wheeler H; Cook R; Teo C; Brazier D; Schembri G; Kastelan M; Guo L; Back MF
ANZ J Surg; 2018 Mar; 88(3):196-201. PubMed ID: 28922698
[TBL] [Abstract][Full Text] [Related]
27. Stemness Marker Detection in the Periphery of Glioblastoma and Ability of Glioblastoma to Generate Glioma Stem Cells: Clinical Correlations.
Raysi Dehcordi S; Ricci A; Di Vitantonio H; De Paulis D; Luzzi S; Palumbo P; Cinque B; Tempesta D; Coletti G; Cipolloni G; Cifone MG; Galzio R
World Neurosurg; 2017 Sep; 105():895-905. PubMed ID: 28559081
[TBL] [Abstract][Full Text] [Related]
28. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
Gainer JL; Sheehan JP; Larner JM; Jones DR
J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
[TBL] [Abstract][Full Text] [Related]
29. Multiple resections and survival of recurrent glioblastoma patients in the temozolomide era.
Ortega A; Sarmiento JM; Ly D; Nuño M; Mukherjee D; Black KL; Patil CG
J Clin Neurosci; 2016 Feb; 24():105-11. PubMed ID: 26671314
[TBL] [Abstract][Full Text] [Related]
30. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
[TBL] [Abstract][Full Text] [Related]
31. Effect of Notch expression in glioma stem cells on therapeutic response to chemo-radiotherapy in recurrent glioblastoma.
Saito N; Aoki K; Hirai N; Fujita S; Iwama J; Hiramoto Y; Ishii M; Sato K; Nakayama H; Harashina J; Hayashi M; Izukura H; Kimura H; Ito K; Sakurai T; Yokouchi Y; Oharazeki T; Takahashi K; Iwabuchi S
Brain Tumor Pathol; 2015 Jul; 32(3):176-83. PubMed ID: 25665548
[TBL] [Abstract][Full Text] [Related]
32. Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma.
Liu B; Liu J; Liao Y; Jin C; Zhang Z; Zhao J; Liu K; Huang H; Cao H; Cheng Q
Med Sci Monit; 2019 May; 25():3624-3635. PubMed ID: 31094363
[TBL] [Abstract][Full Text] [Related]
33. Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution.
Azoulay M; Santos F; Shenouda G; Petrecca K; Oweida A; Guiot MC; Owen S; Panet-Raymond V; Souhami L; Abdulkarim BS
J Neurooncol; 2017 May; 132(3):419-426. PubMed ID: 28374095
[TBL] [Abstract][Full Text] [Related]
34. Pathological spectrum in recurrences of glioblastoma multiforme.
Marucci G; Fabbri PV; Morandi L; De Biase D; Di Oto E; Tallini G; Sturiale C; Franceschi E; Frezza GP; Foschini MP
Pathologica; 2015 Mar; 107(1):1-8. PubMed ID: 26591624
[TBL] [Abstract][Full Text] [Related]
35. Stem cell signature in glioblastoma: therapeutic development for a moving target.
Nakano I
J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
[TBL] [Abstract][Full Text] [Related]
36. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
[TBL] [Abstract][Full Text] [Related]
37. Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide.
Pinel B; Duchesne M; Godet J; Milin S; Berger A; Wager M; Karayan-Tapon L
J Neurooncol; 2017 Apr; 132(2):287-294. PubMed ID: 28070830
[TBL] [Abstract][Full Text] [Related]
38. LGR5 is a proneural factor and is regulated by OLIG2 in glioma stem-like cells.
Mao XG; Song SJ; Xue XY; Yan M; Wang L; Lin W; Guo G; Zhang X
Cell Mol Neurobiol; 2013 Aug; 33(6):851-65. PubMed ID: 23793848
[TBL] [Abstract][Full Text] [Related]
39. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
Garnier D; Meehan B; Kislinger T; Daniel P; Sinha A; Abdulkarim B; Nakano I; Rak J
Neuro Oncol; 2018 Jan; 20(2):236-248. PubMed ID: 29016925
[TBL] [Abstract][Full Text] [Related]
40. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
